Insilico Medicine Unveils AI-Driven Longevity Vaccines to Target Cellular Drivers of Age-Related Diseases

AI-Driven Therapeutic Approach Targets Root Causes of Aging

Insilico Medicine has launched Longevity Vaccines, a research initiative that applies AI-driven drug discovery to develop preventive treatments targeting cellular drivers of age-related diseases. The clinical-stage company announced this expansion of its aging-oriented discovery strategy from small molecules into RNA-encoded, in vivo cell engineering. 1

1

Rather than treating downstream pathology after tissue damage accumulates, the initiative aims to eliminate senescent cells, activated fibroblasts, and autoreactive lymphocytes within a preventive window. These discrete cell populations initiate and sustain many aging-related diseases through well-studied surface markers, including the senescence-associated secretory phenotype (SASP) that secretes pro-inflammatory proteins. 2

2

Programmable Circular RNA Delivers Self-Limiting Cell Engineering

The Longevity Vaccines platform utilizes a programmable delivery modality combining circular mRNA (cmRNA) with targeted lipid nanoparticles. This AI-designed drug chassis delivers short-lived genetic instructions inside the body to arm a patient's own T cells, directing them to recognize and remove specific target cell populations. 1

1

Unlike traditional ex-vivo CAR T-cell therapies requiring complex laboratory engineering and risking prolonged immune overactivation, the in vivo approach offers a self-limiting solution. Circular mRNA resists enzymatic degradation to support durable yet transient protein expression, while targeted lipid nanoparticles ensure selective delivery to endogenous T cells. Once internalized, the genetic instructions temporarily equip host T cells with synthetic receptors targeting diseased cell markers, with the mRNA naturally degrading over time to minimize risks of prolonged immune suppression or off-target exhaustion. 2

2

Pharma.AI Platform Enables Precise Target Selection

Selecting antigens for preventive medicine demands targets that appear at the earliest stages of pathogenesis while offering a wide therapeutic window. Insilico addresses this challenge using its end-to-end Pharma.AI platform, which integrates PandaOmics for multi-omics target discovery, generative biologics for de novo binder design, and Chemistry42 for ionizable lipids and delivery systems. 1

1

The platform ranks candidate surface antigens by evidence strength, expression timing, and tissue specificity against a whole-body surface atlas to verify that targets are absent from vital, healthy organs. Insilico's aging foundation models and Virtual Aging Cell supply the temporal, age-conditioned context required to pinpoint the earliest divergent cell states in a disease trajectory. Candidates undergo validation in automated laboratories, where experimental readouts continuously feed back to refine target rankings and optimize molecular designs. 2

2

Proven Track Record With Rentosertib Success

The initiative builds on Insilico's validated aging-first discovery engine, demonstrated through Rentosertib (ISM001-055), a first-in-class TNIK inhibitor. The AI-designed drug advanced from target identification to preclinical candidate in just 18 months, with its target nominated by AI for its role across multiple hallmarks of aging. Rentosertib recently demonstrated lung capacity restoration in a randomized Phase IIa trial for idiopathic pulmonary fibrosis (IPF) and has entered Phase III development. 1

1

This success established Insilico's dual-purpose strategy of discovering therapeutics that tackle both specific clinical indications and fundamental biological aging processes, which Longevity Vaccines now extends into a preventive, cell-clearing modality.

Immunosenescence as Initial Target for Rejuvenating Aging Tissues

The initiative will first focus on reversing immunosenescence, the progressive deterioration of the immune system with age. As individuals grow older, exhausted and senescent lymphocytes accumulate, causing chronic systemic inflammation, decreasing immune surveillance against malignancies, and reducing vaccine responsiveness. 2

2

By resetting the immune compartment and clearing these culprit cells, researchers aim to rejuvenate aging tissues and restore baseline tissue homeostasis throughout the body. Systemic inflammation driven by an aging immune system is recognized as a key accelerator of neuroinflammation and neurodegenerative pathology in the brain. Additional indications under evaluation include fibrotic disorders and metabolic dysfunction, which share defined initiating cell populations reachable by the same programmable chassis. 1

1

Financial Milestone Supports Expansion

Insilico reported total revenue of approximately $106 million in the first half of 2026, representing a 287% year-over-year increase. The company achieved its first profitable half-year since listing, with an adjusted net profit exceeding $51 million. This milestone was driven by out-licensing, co-development, and R&D collaborations with global partners including Eli Lilly, Servier, Takeda, SK Biopharmaceuticals, Qilu Pharmaceutical, Hygtia Therapeutics, CMS, and Tenacia. 1

1

Founder and co-CEO Alex Zhavoronkov stated the initiative extends Insilico's rigor to preventive medicine, delivering programmable, single-dose therapies that clear the root-cause cells of age-related disease.